Yale University
Also known as: Yale School of Medicine, Yale University School of Medicine, Yale Department of Psychiatry, Yale University Department of Psychiatry, Yale-New Haven Hospital, Yale University
Data updated
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Academic Research
0 papersPublished Papers
0
Trial Involvement
21
Distinct Focus Topics
0
Latest Publication
Unknown
Government funding received
2 grantsVA — MDMA-assisted therapy for PTSD + alcohol use disorder in veterans
2024–2029
First VA-funded psychedelic study. VA researchers affiliated with Brown University and Yale University evaluate MDMA-assisted therapy for veterans with both PTSD and alcohol use disorder. $1.5M over five years. Marks the first time since the 1960s the VA has funded research on psychedelic compounds. Attributed here to Yale (Brown isn't in the Blossom stakeholder set).
SourceNIMH K-award — Psilocybin for treatment-resistant OCD (Kelmendi)
2021
First NIMH grant for a psychedelic research investigation since the 1960s. NIH career-development award to Benjamin Kelmendi, MD (Yale School of Medicine) for pilot psilocybin treatment of refractory OCD. Amount ≈$800K.
SourceEcosystem
3 connectionsPhilanthropic Funders
Support for research into psilocybin for OCD and headache disorders
Jan 1, 2018
undisclosed
Carey Turnbull Wears Many Hats as a Donor and InvestorAssisted the founding of Yale University's psilocybin research program
Jan 1, 2020
undisclosed
Carey Turnbull - Heffter Research InstitutePsilocybin treatment for obsessive-compulsive disorder (OCD)
Jan 1, 2022
undisclosed
Heffter Research Institute 2022 NewsletterResearch journey
Built from the 47 trials Yale University has sponsored, placed at the date each one started.
Featured in topic journeys
Clinical research timelines that include a curated milestone from Yale University.
Quick Facts
- Type
- academic
- HQ
- United States
- Website
- Visit
Research Landscape
What the registered trials Yale University sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of August 2026.
How fast is Yale University research growing?
SourcedRegistered trials by recorded study-start year; 2 earlier trials began before 2012. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (48 of 48 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
What's live right now, and what stopped?
SourcedRegistry status of all 48 Yale University trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Which conditions does Yale University run trials on?
SourcedTrials per primary indication. Orange marks the largest research focus.
Don't read shares as adding to 100%: a trial with several primary indications counts once per indication. Trial volume signals research attention, not evidence quality.
Which compounds appear in Yale University trials?
SourcedTrials per compound. Orange marks the most-studied compound.
Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.
Sponsored Trials
20The Effects of Psilocybin on Social Connectedness
- Start Date
- Compounds
- Placebo, Psilocybin
Psilocybin Microdosing on Cognition, Mood and Quality of Life
- Start Date
- Compounds
- Psilocybin, Placebo
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
- Start Date
- Compounds
- Psilocybin
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
- Start Date
- Compounds
- Psilocybin, Placebo
MDMA in Borderline Personality Disorder (MDMA in BPD)
- Start Date
- Compounds
- MDMA
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
- Start Date
- Compounds
- DMT, Placebo
Psychedelic Virtual Reality
- Start Date
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
- Start Date
- Compounds
- Psilocybin
Mechanistic Studies of Psilocybin in Headache Disorders
- Start Date
- Compounds
- Psilocybin, Placebo
PCORI Comparative Effectiveness Study-Esketamine (Spravato) Vs. Ketamine-Equivalence Study
- Start Date
- Compounds
- Ketamine, Esketamine
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
- Start Date
- Compounds
- Placebo
Open-Label Psilocybin
- Start Date
- Compounds
- Psilocybin
Role Of Non-Specific Effects in The Treatment of Depression With Esketamine (ROSETTE)
- Start Date
Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment
- Start Date
The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD
- Start Date
- Compounds
- MDMA, Placebo
The OBSERVE Protocol
- Start Date
- Compounds
- Ketamine, Esketamine
Long Term Follow Up KET-PD
- Start Date
- Compounds
- Ketamine, Placebo
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
- Start Date
- Compounds
- Ketamine
Effects of Repeated Psilocybin Dosing in OCD
- Start Date
- Compounds
- Psilocybin
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- Start Date
- Compounds
- Ketamine, Placebo
Where this pipeline sits in the field
Yale University runs late-stage trials that Blossom ranks by how soon a catalyst is expected, alongside every other Phase 2 and Phase 3 study in the field.
Collaborated Trials
1Recent activity
- StartedThe Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease (NCT07610369, psilocybin)
- TerminatedComputer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics (NCT06624137)
- CompletedPsychedelic Virtual Reality (NCT06581263)
- NewsClearmind Medicine treated the last patient in the first cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder, with six patients enrolled and two Israeli sites activated.GlobeNewswire
- CompletedKetamine for the Treatment of Depression in Parkinson's Disease (NCT04944017, ketamine)
- StartedMDMA in Borderline Personality Disorder (MDMA in BPD) (NCT06683014, mdma)
- StartedThe Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) (NCT06070649, dmt)
- StartedPsychedelic Virtual Reality (NCT06581263)